Progression and treatment of HER2-positive breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 4, 2010, Pages 611-623

  Davoli, April ^a   Hocevar, Barbara A ^b   Brown, Thomas L ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Combination therapy; Crosstalk; HER2; Hormone receptor; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; CAPECITABINE; CARBOPLATIN; CELL SURFACE RECEPTOR; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FADROZOLE; FLUOROURACIL; GEFITINIB; GEMCITABINE; GENISTEIN; LAPATINIB; LETROZOLE; METHOTREXATE; MONOCLONAL ANTIBODY; NAVELBINE; NERATINIB; PERTUZUMAB; PROGESTERONE RECEPTOR; RESVERATROL; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ALOPECIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CARDIOTOXICITY; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL GROWTH; CELL MEMBRANE; CELL SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EVOLUTIONARY HOMOLOGY; FOOD AND DRUG ADMINISTRATION; HEART DISEASE; HORMONAL THERAPY; HUMAN; MEDICAL SOCIETY; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR GROWTH; ANIMAL; ARTICLE; BIOLOGICAL MODEL; BREAST TUMOR; DISEASE COURSE; DRUG RESISTANCE; DRUG SCREENING; DRUG THERAPY; FEMALE; IMMUNOLOGY; METABOLISM; METHODOLOGY; PATHOLOGY; SURVIVAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY; FEMALE; HUMANS; MODELS, BIOLOGICAL; RECEPTOR CROSS-TALK; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS;

EID: 75749112563     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1208-1     Document Type: Short Survey

References (64)

1. A Jemal R Siegel E Ward, et al. 2008 Cancer statistics, 2008 Cancer J Clin 58 71 96 10.3322/CA.2007.0010
2. A Prat J Baselga 2008 The role of hormone therapy in the management of the hormonal-receptor-positive breast cancer with co-expression of HER2 Nat Clin Pract Oncol 5 9 531 542 10.1038/ncponc1179 1:CAS:528:DC%2BD1cXhtVGgt7fE 18607391
3. JMS Bartlett JJ Going EA Mallon, et al. 2001 Evaluating HER2 amplification and expression in breast cancer J Pathol 195 422 428 10.1002/path.971 1:CAS:528:DC%2BD3MXovVGgsb4%3D 11745673 (Pubitemid 33069666)
4. A Lipton SM Ali K Leitzel, et al. 2002 Elevated Serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer J Clin Oncol 20 6 1467 1472 10.1200/JCO.20.6.1467 1:CAS:528:DC%2BD38XivFeisbk%3D 11896093 (Pubitemid 34260524)
5. JC Chang 2007 HER2 inhibition: from discovery to clinical practice Clin Cancer Res 13 1 3 10.1158/1078-0432.CCR-06-2405 17200331 (Pubitemid 46121845)
6. I Rubin Y Yarden 2001 The basic biology of HER2 Ann Oncol 12 Suppl. 1 S3 S8 10.1023/A:1011195320446 11521719
7. T Cooke 2000 What is HER2? Eur J Oncol Nurs 4 suppl I 2 9 10.1054/ejon.2000.0072 1:STN:280:DC%2BD3szitVamsg%3D%3D 12849611
8. JS Ross JA Fletcher GP Linette, et al. 2003 The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy Oncol 8 307 325 10.1634/theoncologist.8-4-307 1:CAS:528:DC%2BD3sXmvFSqt74%3D (Pubitemid 36929717)
9. Y Liu D El-Ashry D Chen, et al. 1995 MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo Breast Cancer Res Treat 34 97 117 10.1007/BF00665783 1:CAS:528:DyaK2MXls1Knt7k%3D 7647336
10. H Kurokawa AEG Lenferink JF Simpson, et al. 2000 Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells Cancer Res 60 5887 5894 1:CAS:528:DC%2BD3cXnvVSntLw%3D 11059787
11. KC Osborne V Bardou TA Hopp 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer J Natl Cancer Inst 95 5 353 361 1:CAS:528:DC%2BD3sXivVeqsrg%3D 12618500
12. J Shou S Massarweh KC Osborne, et al. 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 96 12 926 935 1:CAS:528:DC%2BD2cXltVWmtLY%3D 15199112
13. KC Osborne 1998 Tamoxifen in the treatment of breast cancer N Engl J Med 339 22 1609 1618 10.1056/NEJM199811263392207 1:CAS:528:DyaK1cXnvFOitLs%3D 9828250 (Pubitemid 28536137)
14. R Schiff SA Massarweh J Shou, et al. 2004 Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance Clin Cancer Res 10 331s 336s 10.1158/1078-0432.CCR-031212 1:CAS:528:DC%2BD2cXkvF2ksw%3D%3D 14734488 (Pubitemid 38116639)
15. CL Smith Z Nawaz BW O'Malley 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen Mol Endocrinol 11 6 657 666 10.1210/me.11.6.657 1:CAS:528:DyaK2sXjtl2lt78%3D 9171229 (Pubitemid 27225293)
16. M Razandi A Pedram ST Park ER Levin 2003 Proximal events in signaling by plasma membrane estrogen receptors J Biol Chem 278 4 2701 2712 10.1074/jbc.M205692200 1:CAS:528:DC%2BD3sXksFaktw%3D%3D 12421825 (Pubitemid 36801351)
17. J Font De Mora M Brown 2000 A1B1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor Mol Cell Biol 20 14 5041 5047 10.1128/MCB.20.14.5041-5047.2000 1:STN:280:DC%2BD3czisFehug%3D%3D 10866661 (Pubitemid 30431558)
18. Hendriks BS, Orr G, Wells A, Wiley HS, Lauffenburger DA (2005) Parsing ERK activation reveal quantitatively equivalent contributions from EGFR and HER2 in human mammary epithelial cells. J Biol Chem 280:6157-6169
19. MA Cobleigh CL Vogel D Tripathy, et al. 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 9 2639 2648 1:CAS:528:DyaK1MXmtlWrurk%3D 10561337
20. MJ Piccart-Gebhart M Procter B Leyland-Jones, et al. 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 16 1659 1672 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L 16236737 (Pubitemid 41464705)
21. CL Vogel MA Cobleigh D Tripathy, et al. 2002 Efficacy and Safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 3 719 726 10.1200/JCO.20.3.719 1:CAS:528:DC%2BD38XhsVGmt7o%3D 11821453 (Pubitemid 34111379)
22. C Vogel MA Cobleigh D Tripathy, et al. 2001 First-line, single-agent Herceptin (trastuzumab) in metastatic breast cancer: a preliminary report Eur J Cancer 37 S25 S29 10.1016/S0959-8049(00)00405-6 1:CAS:528:DC%2BD3MXpsVeksA%3D%3D 11167088
23. CL Vogel MA Cobleigh D Tripathy, et al. 2001 First-line herceptin monotherapy in metastatic breast cancer Oncology 61 suppl 2 37 42 10.1159/000055400 1:CAS:528:DC%2BD3MXovFWjsLg%3D 11694786 (Pubitemid 33033423)
24. TM Suter N Cook-Bruns C Barton 2004 Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer Breast 13 173 183 10.1016/j.breast.2003.09.002 1:STN:280:DC%2BD2c3nsl2gtw%3D%3D 15177418 (Pubitemid 38937119)
25. HJ Burstein AM Storniolo S Franco, et al. 2008 A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer Ann Oncol 19 1068 1074 10.1093/annonc/mdm601 1:STN:280:DC%2BD1czktlSgsA%3D%3D 18283035 (Pubitemid 351796331)
26. R Nahta LXH Yuan Y Du FJ Esteva 2007 Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling Mol Cancer Ther 6 2 667 674 10.1158/1535-7163.MCT-06-0423 1:CAS:528:DC%2BD2sXhvVWrsbc%3D 17308062 (Pubitemid 46332467)
27. J Baselga J Albanell A Ruiz, et al. 2005 Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer J Clin Oncol 23 5323 5333 10.1200/JCO.2005.08.326 1:CAS:528:DC%2BD2MXpslOrtLs%3D 15939921 (Pubitemid 46206986)
28. HL Gomez DC Doval MA Chavez, et al. 2008 Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer J Clin Oncol 26 18 2999 3005 10.1200/JCO.2007.14.0590 1:CAS:528:DC%2BD1cXoslOqsLo%3D 18458039
29. D Avigan B Vasir J Gong, et al. 2004 Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses Clin Cancer Res 10 4699 4708 10.1158/1078-0432.CCR-04-0347 1:CAS:528:DC%2BD2cXlvVegsr4%3D 15269142 (Pubitemid 38955520)
30. ML Disis TA Gooley K Rinn, et al. 2002 Generation of T-Cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines J Clin Oncol 20 11 2624 2632 10.1200/JCO.2002.06.171 1:CAS:528:DC%2BD38XkvF2mtr8%3D 12039923 (Pubitemid 34575634)
31. ML Disis K Schiffman K Guthrie, et al. 2004 Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein-based vaccine J Clin Oncol 22 10 1916 1925 10.1200/JCO.2004.09.005 1:CAS:528:DC%2BD2cXptlCksrk%3D 15143085 (Pubitemid 41095184)
32. R Jakesz W Jonat M Gnant, et al. 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ANCSG trial 8 and ARNO 95 trial Lancet 366 455 462 10.1016/S0140-6736(05)67059-6 1:CAS:528:DC%2BD2MXntVeisLw%3D 16084253 (Pubitemid 41111693)
33. MJ Ellis A Coop B Singh, et al. 2001 Letrozole is more effective Neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or Erb-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 18 3808 3816 1:CAS:528:DC%2BD3MXnsVKqsbo%3D 11559718
34. H Mouridsen M Gershanovich Y Sun, et al. 2001 Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer group J Clin Oncol 19 10 2596 2606 1:CAS:528: DC%2BD3MXkt1OmurY%3D 11352951
35. M Kaufmann W Jonat J Hilfrich, et al. 2007 Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study J Clin Oncol 25 19 2664 2669 10.1200/JCO.2006.08.8054 1:CAS:528: DC%2BD2sXosValt7Y%3D 17563395 (Pubitemid 47123171)
36. HB Muss AD Thor DA Berry, et al. 1994 c-erbB-2 Expression and response to adjuvant therapy in women with node-positive early breast cancer N Engl J Med 330 18 1260 1266 10.1056/NEJM199405053301802 1:STN:280:DyaK2c7psFensQ%3D%3D 7908410 (Pubitemid 24129958)
37. S Paik J Bryant E Tan-Chiu, et al. 2000 HER2 and choice of adjuvant chemotherapy for invasive breast cancer: national surgical adjuvant breast and bowel project protocol B-15 J Natl Cancer Inst 92 24 1991 1998 10.1093/jnci/92.24.1991 1:CAS:528:DC%2BD3MXkvF2rsw%3D%3D 11121461
38. T Petit M Wilt M Velten, et al. 2004 Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy Eur J Cancer 40 205 211 10.1016/S0959-8049(03)00675-0 1:CAS:528:DC%2BD2cXjsVOlsA%3D%3D 14728934 (Pubitemid 38077022)
39. KI Pritchard LE Shepherd FP O'Malley, et al. 2006 HER2 and responsiveness of breast cancer to adjuvant chemotherapy N Engl J Med 354 20 2103 2111 10.1056/NEJMoa054504 1:CAS:528:DC%2BD28XkslCku7s%3D 16707747 (Pubitemid 43736610)
40. M Tanner J Isola T Wiklund, et al. 2006 Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian breast group trial 9401 J Clin Oncol 24 16 2428 2436 10.1200/JCO.2005.02.9264 1:CAS:528:DC%2BD28XmtVOmsLc%3D 16682728 (Pubitemid 46630618)
41. MN Levine VH Bramhall KI Pritchard, et al. 1998 A randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methrotrexate, and fluorouracil in premenopausal women with node positive breast cancer J Clin Oncol 16 2651 2658 1:CAS:528: DyaK1cXlsFCguro%3D 9704715
42. MN Levine KI Pritchard VH Bramhall, et al. 2005 A randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methrotrexate, and fluorouracil in premenopausal women with node positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5 J Clin Oncol 23 5166 5170 10.1200/JCO.2005.09.423 1:CAS:528: DC%2BD2MXpsFWmtb8%3D 16051958 (Pubitemid 46224025)
43. A Gennari MP Sormani P Pronzato, et al. 2008 HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials J Natl Cancer Inst 100 1 14 20 1:CAS:528:DC%2BD1cXit1Cku7o%3D 18159072
44. JL Limer V Speirs 2004 Phytoestrogens and breast cancer chemoprevention Breast Cancer Res 6 3 119 127 10.1186/bcr781 1:CAS:528:DC%2BD2cXotVSlu7c%3D 15084232 (Pubitemid 38607665)
45. L-J Lu KE Anderson JJ Grady F Kohen M Nagamani 2000 Decreased ovarian hormones during a soya diet: implications for breast cancer prevention Cancer Res 60 4112 4121 1:CAS:528:DC%2BD3cXlvFOkt74%3D 10945618
46. NB Kumar A Cantor K Allen D Riccardi CE Cox 2002 The specific role of isoflavones on estrogen metabolism in premenopausal women Cancer 94 1166 1174 10.1002/cncr.10320 1:CAS:528:DC%2BD38XitVKhsLo%3D 11920488 (Pubitemid 34150873)
47. BJ Grube ET Eng Y-C Kao A Kwon S Chen 2001 White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation J Nutr 131 3288 3293 1:CAS:528:DC%2BD3MXpt1Gjuro%3D 11739882
48. W Lu L-J M Cree S Josyula M Nagamani JJ Grady KE Anderson 2000 Increased urinary excretion of 2-hydroxyestrone but not 16α-hydroxyestrone in premenopausal women during a soya diet containing isoflavones Cancer Res 60 1299 1305 10728690
49. MS Sakla NS Shenouda PJ Ansell RS MacDonald DD Lubahn 2007 Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells Endocrine 32 69 78 10.1007/s12020-007-9006-1 1:CAS:528:DC%2BD2sXhsVersbfJ 17992604 (Pubitemid 350242549)
50. M Provinciali F Re A Donnini, et al. 2005 Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice Int J Cancer 115 36 45 10.1002/ijc.20874 1:CAS:528:DC%2BD2MXjslejtbg%3D 15688416 (Pubitemid 40559666)
51. J Baselga 2001 Herceptin Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials Oncology 61 suppl 2 14 21 10.1159/000055397 1:CAS:528:DC%2BD3MXovFWjsL0%3D 11694783
52. DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metatstatic breast cancer that overexpresses HER2 N Engl J Med 334 11 783 792 10.1056/NEJM200103153441101 (Pubitemid 32222155)
53. AU Buzdar NK Ibrahim D Francis, et al. 2005 Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23 3676 3685 10.1200/JCO.2005.07.032 1:CAS:528:DC%2BD2MXlslWntr8%3D 15738535 (Pubitemid 46252462)
54. J Hurley P Doliny I Reis, et al. 2006 Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer J Clin Oncol 24 12 1831 1838 10.1200/JCO.2005.02.8886 1:CAS:528:DC%2BD28XkvVajt7k%3D 16549824 (Pubitemid 46638980)
55. MD Pegram T Pienkowski DW Northfelt, et al. 2004 Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer J Natl Cancer Inst 96 10 759 769 1:CAS:528:DC%2BD2cXkt1Sqsbg%3D 15150304
56. R Nahta FJ Esteva 2006 Molecular mechanisms of trastuzumab resistance Breast Cancer Res 8 6 667 674 10.1186/bcr1612 (Pubitemid 44804004)
57. D Cameron M Casey M Press, et al. 2008 A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses Breast Cancer Res Treat 112 533 543 10.1007/s10549-007-9885-0 1:CAS:528:DC%2BD1cXhtl2mu7bI 18188694
58. PK Marcom C Isaacs L Harris, et al. 2007 The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers Breast Cancer Res Treat 102 43 49 10.1007/s10549-006-9307-8 1:CAS:528: DC%2BD2sXhslCltr8%3D 16897431 (Pubitemid 46294957)
59. R Nahta M-C Hung FJ Esteva 2004 The HER2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells Cancer Res 64 2343 2346 10.1158/0008-5472.CAN-03-3856 1:CAS:528: DC%2BD2cXis1yjt7k%3D 15059883 (Pubitemid 38523885)
60. R Swaby K Blackwell Z Jiang, et al. 2009 Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study J Clin Oncol 27 15S 1004
61. GD Lewis Philips G Li DL Dugger 2008 Targeting HER2 positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res 68 9280 10.1158/0008-5472.CAN-08-1776
62. A Kamal L Thao J Sensintaffer, et al. 2003 A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors Nature 425 407 410 10.1038/nature01913 1:CAS:528:DC%2BD3sXnsV2kt7w%3D 14508491 (Pubitemid 37187270)
63. K Yu L Toral-Barza C Discafani, et al. 2001 mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer Endocr Relat Cancer 8 249 258 10.1677/erc.0.0080249 11566616 (Pubitemid 32947647)
64. B Moy PE Goss 2006 Lapatinib: current status and future directions in breast cancer Oncol 11 10 1047 1057 10.1634/theoncologist.11-10-1047 1:CAS:528:DC%2BD28XhtlCmu73N (Pubitemid 44788395)